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Abstract
Background: CD133 is known to be a cancer stem cell (CSC) marker. However, recent studies have revealed that
CD133 is not restricted to CSC but to be expressed not only in human normal tissues but also in some cancers
and could serve as a prognostic factor for the patients. Nevertheless, the expression of CD133 in human
cholangiocarcinoma (CC) is rare and our study is to detect the expression and explore the potential functions of
CD133 in human CC.
Methods: Fifty-nine cases, comprised of 5 normal liver tissues and 54 consecutive CC specimens (21 well-
differentiated, 12 moderately-differentiated and 21 poorly-differentiated), were included in the study.
Immunohistochemical stainning with CD133 protein was carried out, and statistical analyses were performed.
Results: CD133 was found to express in all 5 normal livers and 40 out of 54 (74%) CC tissues with different
subcellular localization. In the well, moderately and poorly differentiated cases, the numbers of CD133 positive
cases were 19 (19 of 21, 90%), 10 (10 of 12, 83%) and 11 (11 of 21, 52%) respectively. Further statistical analyses
indicated that the expression and different subcellular localization of CD133 were significantly correlated with the
differentiation status of tumors (P=0.004, P = 0.009). Among 23 patients followed up for survival, the median
survival was 4 months for fourteen CD133 negative patients but 14 months for nine CD133 positive ones. In
univariate survival analysis, CD133 negative expression correlated with poor prognosis while CD133 positive
expression predicted a favorable outcome of CC patients (P=0.001).
Conclusions: Our study demonstrates that CD133 expression correlates with the differentiation of CC and indicates
that CD133 is a potential indicator for differentiation and prognosis of human CC.
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Background
CD133, also known as prominin-1, is a five-transmem-
brane domain molecule [1,2] located on apical plasma
membrane protrusions of embryonic epithelial structures
[3-5]. Up to now, it is mainly used for marking stem-like
cells of various tissues and cancers [6]. Many tumors are
known to contain a minority population of cancer stem
cells or tumor-initiating cells which have the properties
of self-renewal, proliferation, and multilineage differen-
tiation and are responsible for sustaining the tumor [7].
M o r e o v e r ,C D 1 3 3m a yr e p r e s e n tap u t a t i v ec a n c e rs t e m
cell marker in many solid tumors, such as human colon
cancer [8,9], prostate tumor [10,11], pancreatic adenocar-
cinoma [12], renal cancer [13], neural tumor [14-17], and
hepatocellular carcinoma [18,19].
It has been shown that CD133 is an apical molecule
not only in embryonic epithelial structures, but also in
many normal human tissues and its expression is not
restricted to stem cells in pancreatic tissues [20]. In
addition, CD133 has been found to be a prognostic fac-
tor of some cancers, such as colon and hepatocellular
carcinoma [21,22]. Recently, Shimada et al. reported
that normal bile duct epithelia were entirely negative for
CD133 while 14 out of 29 CC cases expressed CD133.
However, for each case, only a few tumor cells
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rate in the CD133-positive group was worse than that in
the CD133-negative group [23]. On the contrary, in our
study we detected the expression of CD133 in human
CC specimens by immunohistochemistry and analyzed
its correlation with clinical and histopathological fea-
tures. We found that CD133 was expressed on apical
membrane of normal bile ducts and apical membrane
or/and in the cytoplasma of CC tissues. The positive
expression of CD133 on tumor cells was significantly
correlated with well or moderately differentiated CC
cases and predicted a better prognosis for the patients.
Methods
Clinical samples
Paraffin-embedded liver tissues from 54 consecutive
patients with CC were retri e v e df r o mt h ep a t h o l o g y
archives of Xijing Hospital between 2003 and 2007. In
addition, 5 normal liver tissues were collected from the
donor livers. The CC patients consisted of 28 males and
26 females with a mean age of 59.4 years (range from
34 to78 years). And the tumor specimens were com-
posed of 25 cases of intrahepatic CC (ICC) and 29 cases
of hilar CC (HCC) (Table 1). The patients’ charts were
reviewed and those who had pre-operative radiation or
chemotherapy, or were immunocompromised, were
excluded. All the histological slides were re-examined by
t w op a t h o l o g i s t st oe n s u r ec o r r e c td i a g n o s i so fC Ca n d
the degree of its differentiation was evaluated in each
case. Histological grading of CC was assessed based on
the World Health Organization Classification of Tumors
[24]. Among the 54 cases, 21 were well-differentiated,
12 were moderately-differentiated and 21 were poorly-
differentiated. For clinical staging, 18 cases were at stage
I/II while the other 36 were at stage III/IV. Moreover,
23 patients were followed up for survival from the date
of surgery to March 31, 2008, including only that cacer-
specific death of CC, the details of which were listed in
additional file 1. Specimen collection and study proce-
dures were approved by the Ethics Committee of Xijing
Hospital.
Immunohistochemistry
Paraffin sections of 4 μm thickness were deparaffinized
and treated with 3% (v/v) hydrogen peroxide to block
endogenous peroxidase activity. Heat-induced antigen
retrieval was performed in 0.01 M sodium citrate (pH
6.0), followed by incubation in 10% (v/v) bovine serum
albumin (BSA; Sigma, St Louis, MO, USA) in PBS
(Phosphate Buffered Saline) at room temperature for 10
minutes to block the non-specific antibody-binding
sites. The sections were then incubated overnight at 4°C
with the rabbit monoclonal antibody against the human
CD133 proteins (1:100 dilution; clone C24B9, Cell Sig-
naling Technology, Danvers, MA, USA). Later on, a
standard rapid EnVision technique (REAL™ EnVision™
Detection System, Peroxidase/DAB+, Rabbit/Mouse,
Code K5007, Dako, Denmark) was used to detect the
protein conjugates and develop the color. Finally, the
sections were visualized after counterstaining with
hematoxylin. Serial sections of CC were run in parallel
with the primary antibody replaced by PBS and rabbit
IgG1 (AMS/Immunokontact, Abingdon, UK) as blank
and negative controls. The whole sections were screened
for CD133 expression and the cholangiocarcinoma cases
were defined as CD133 positive if CD133 staining was
detected in more than 10% of the entire tumor area
[25]. The slides were viewed under 100 × magnifications
to define subcellular localization of the protein in the
tumor glands. The evaluation of CD133 staining was
carried out by two pathologists who had no knowledge
of clinicopathological features of the cases.
Statistics
Statistical analyses were performed using Statistical Pro-
gram for Social Sciences (SPSS) software (Version 17.0,
SPSS Inc, Chicago, USA). A Spearman correlation was
used to analyze the correlation between the expression
of CD133 and the clinicopathological features. The
Kaplan-Meier analysis was also used to estimate tumor-
specific survival, and different groups were compared
with the log-rank test. For multivariate analysis, the
COX regression model was used [26]. All tests were
two-sided. P < 0.05 was considered significant.
Results
CD133 Expresses on Normal Bile Duct Epithelia and Most
of the CC Tumor Cells with Different Subcelluar
Localization
In the normal liver tissues, CD133 expression was found
mainly on the apical membrane surface of bile ducts of
all sizes (Figure 1A-C) but was not seen in hepatocytes,
hepatic vessels and sinusoidal lining cells. In CC tissues,
40 of 54 cases (74%) were positive for CD133.
Table 1 The origin and differentiation degree of the 54
cases of CC
Origin Differentiation degree ICC HCC Subtotal
Well-differentiated glandular carcinoma 7 14 21
Moderately-differentiated glandular carcinoma 5 7 12
Poorly glandular carcinoma 13 8 21
Subtotal 25 29 54
ICC: Intrahepatic cholangiocarcinoma; HCC: Hilar cholangiocarcinoma
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Page 2 of 8The subcellular localization of the CD133 protein was
investigated and three staining patterns, i.e. apical mem-
brane, cytoplasm or both, were identified in CC (Figure
2D-F). In addition, some normal bile ducts (Figure 1B)
and most CD133-positive tumors showed the shedding
of CD133 positive cellular debris into the glandular
lumina (Figure 2E).
The Expression and Different Subcellular Localization of
CD133 Correlate with the Differentiation Status of CC
Tumors
In the well, moderately and poorly differentiated CC, the
numbers of CD133 positive cases were 19 (19 of 21,
90%), 10 (10 of 12, 83%) and 11 (11 of 21, 52%) respec-
tively. Spearman correlation test showed that the
Figure 1 Immunohistochemical staining of CD133 in normal human liver tissues. CD133 expression was found mainly on the apical
membrane surface of bile ducts of different sizes in normal liver tissue. (A) Normal small bile ducts, original magnification 200×; (B) Reactive bile
ducts, original magnification 200×; (C) Large bile duct, original magnification 400×. In addition, CD133-positive cellular debris in the glandular
lumina was observed in some normal bile ducts (B, arrow).
Figure 2 The expression and different subcellular localization of CD133 in CC. Among the CD133-positive cholangiocarcinoma, three
staining patterns were identified: the well-differentiated tumors (A) were stained mostly on the apical membrane (D) or both membrane and
cytoplasm (E) but the majority of moderately (B) and poorly differentiated (C) tumors were stained in the cytoplasm (F) or both membrane and
cytoplasm, original magnification 400×. Also, in some cases, CD133-positive cellular debris was observed in the malignant glandular lumina (E).
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Page 3 of 8expression of CD133 was significantly correlated with
well or moderately differentiated CC (P = 0.004, Table
2), which implied that the positive expression meant
higher differentiation status of tumors while the absence
of CD133 signified poorly differentiated ones.
Among the 40 cases of CD133-positive expression, the
well-differentiated tumors were stained mostly on the
membrane or on the both membrane and in the cyto-
plasm (17 of 19, 89%) but the majority of moderately
and poorly differentiated tumors were stained in the
cytoplasm or both on the membrane and in the cyto-
plasm (8/10, 80% and 10/11, 91%, respectively); more-
over, by statistical anlysis, the different subcellular
localization of CD133 correlated with the differentiation
status of the tumor (P=0.009, Table 2). However, the
a g ea n dg e n d e ro ft h ep a t i e n t sd i dn o tc o r r e l a t ew i t h
the CD133 expression or the differentiation status of CC
(P> 0.05).
CD133 Negative Expression in CC Predicts Worse
Outcome
Twenty-three patients were followed up for survival.
Among them, 14 cases were CD133 positive and the
other 9 cases were CD133 negative in their tumors.
Using Kaplan-Meier analysis, the median survival was 4
months for CD133 negative patients and 14 months for
the positive ones. Log-rank test showed that the CD133
positive patients had a significantly better survival than
negative ones (P=0.001) and the negative expression of
CD133 was a worse prognostic indicator for patients
with CC (Figure 3). The univariate analysis indicated
that the differentiation status (P =0 . 0 2 5 ) ,s t a g i n g(P =
0.006) and gender (P = 0.005) were also significant prog-
nostic indicators, with the less well differentiated tumor
and male gender predicating for poor overall survival
for patients with CC (Table 3). To clarify the indepen-
dent prognostic value of the CD133 expression in the
patients with CC, a multivariate analysis of the relevant
parameters was performed. The COX regression analysis
revealed that CD133 expression (P =0 . 0 0 7 )a n dt h e
differentiation status (P = 0.010) were prognostic factors
for overall survival (Table 3).
Discussion
In this study, we investigated CD133 expression in nor-
mal human liver tissues and CC tissues using the immu-
nohistochemical method. We found that CD133 was
expressed in human normal livers but the expression
was restricted to biliary trees on the apical membrane.
In CC, 40 of 54 (74%) cases studied showed CD133
expression with different degrees. Similar to colon and
mammary gland adenocarcinoma which have high
expression of CD133 in well or moderately differentiated
tumors [27], most of the well or moderately differen-
tiated CC (90% and 83%, respectively) expressed CD133
and moreover, most CD133 negative CC tumors (71%)
were poorly differentiated.
Table 2 CD133 expression in CC
CC Well differentiated Moderately differentiated Poorly differentiated Subtotal
Number of cases 21 12 21 54
CD133 negative 2 2 10 14
CD133 positive 19 (90%) 10 (83%) 11 (52%) 40 (74%) *#
Membrane 8 2 1 11
Membrane & Cytoplasm 9 4 5 18
Cytoplasm 2 4 5 11
* P = 0.004 (CD133 positivity correlates with differentiation status);
# P = 0.009 (CD133 subcelluar localization correlates with differentiation status)
P < 0.05 is considered significant
Figure 3 CD133 negative expression correlates with poor
survival in CC. Kaplan-Meier survival curve showed the association
between CD133 positive and negative expression in 23 patients
with CC. Fourteen patients with positive CD133 expression had
mean overall survival of 14 months versus 4 months for nine
patients with CD133 negative expression. The log-rank test
demonstrated CD133 negative expression correlated with poor
outcome in CC (P = 0.001).
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Page 4 of 8Our study and other researches have found that
CD133 expression pattern varies in different cancers. In
colorectal carcinoma, CD133 positivity is restricted only
to the luminal surface [21,28]. In our study, besides the
luminal surface pattern in most well-differentiated CC
cases, most of moderately or poorly differentiated CC
cases showed cytoplasmic or both cytoplasmic and
membranous staining (Table 2). It is believed that the
different subcellular localization of CD133 (cytoplasm or
membrane) may confer different cellular functions [20].
The protein is expressed apically on the membrane of
epithelial cells when a lumen has been formed but it is
expressed in the cytoplasm of solidly arranged malignant
tissues of non-epithelial origin [20]. It is well known
that if a formed lumen is observed in an epithelial
tumor, it usually indicates for better differentiation of
the glandular tumor. In our study, CD133 showed cyto-
plasmic expression in many CC cases, suggesting that
cytoplasmic CD133 expression should be not just
restricted to malignant tissues of non-epithelial origin
[20] but also occurs in malignant epithelial cells of CC.
The statistical analysis showed that CD133 expression
significantly correlated with the differentiation status of
CC (P=0.004). It is possible that the expression of
CD133 on the apical membrane may indicate a particu-
lar stage of the cell differentiation connected with the
formation of lumen and ducts as same as the normal
bile ducts, and this deduction is confirmed by Shmelkov,
S.V. et al in their study [28]. In addition, we noticed the
CD133 positive debris in normal bile ducts and the
shedding of CD133 positive tumor cells and apparent
non-cellular, CD133-positive materials in the malignant
ducts. This observation is in accordance with the pre-
vious report that small membrane vesicles containing
prominin-1 were found in the human normal saliva and
tears as well as malignant lumen of colorectal cancer
[29,30]. The concentration of CD133, presented within
the apical membrane of glands or in extracellular mem-
branous vesicles, suggests that this cholesterol-binding
glycoprotein might play a role in regulating the secreting
process [29,31]. Similarly, CD133 expression in normal
bile ducts and its immunoreactivity associated with the
secretion therein indicate that CD133 protein might
exist in bile, thus, a quantitive analysis of CD133 in bile
might be helpful for distinguishing CC from hepatocel-
lular carcinoma.
Table 3 Prognostic variables for survival in 23 patients with CC
Variables Number of cases Median survival in months (range) Univariate analysis
(P value)
Multivariate analysis
(P value)
Age
< 60 14 14.00
(11.12-16.88)
0.058 0.086
>6 0 9 1 1
(3.82-18.21)
Gender
Male 13 11
(7.15-14.85)
0.005 0.116
Female 10 17
(10.49-23.51)
Differentiation status
Well 8 15
(12.8-17.1)
0.025 0.010
Moderately 6 8
(2.24-13.7)
Poorly 9 8
(0-19.7)
Staging
I/II 6 14
(12.5-15.5)
0.033 0.321
III/IV 17 11
(4.9-17.1)
CD133 expression
Positive 14 14
(11.9-16.1)
0.001 0.007
Negative 9 4
(0-8.2)
P < 0.05 is considered significant
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Page 5 of 8Many previous researches have demonstrated the
importance of CD133 as a defining factor of the cancer
stem cell phenotype, including human liver cell line [19]
and hepatocellular carcinoma [32]. In this study, how-
ever, we found that CD133 was commonly expressed on
the apical membrane of all normal bile ducts and was
frequently expressed in the majority of CC cases, which
were clearly at the differentiation stages beyond the
stem/progenitor cells. Other studies also find that the
overall expression of human CD133 is beyond the rare
primitive cells and appears to be a general marker for
apical membrane of fully differentiated glandular epithe-
lia [4,20,28,33]. These findings suggest that it should be
inappropriate to employ CD133 as morphological char-
acterization of cancer stem cells and the value of CD133
expression as a marker for cancer stem cells should be
critically evaluated in future studies [34].
Recently, several studies have reported that the pre-
s e n c eo fC D 1 3 3i nv a r i o u st u m o r si sc o r r e l a t e dw i t h
poor prognosis. Zeppernick [35] and Beier [17] have
found that CD133 expression indicates shorter survival
for adverse gliomas and high-grade oligodendroglial
tumors. Similarly, the high expression of CD133 in col-
orectal adenocarcinoma is related to poor survival of the
patients [21,25]. Furthermore, the high expression of
CD133 is correlated with the increased tumor grade,
advanced disease stage, elevated serum alpha-fetoprotein
levels and poor survival of the patients with hepatocellu-
lar carcinoma [21]. In this study, we found that CD133
expression is also significantly associated with the survi-
val of the patients with CC. However, there are differ-
e n c e sb e t w e e no u rf i n d i n g sa n dt h ep r e v i o u sr e p o r t s .
Firstly, the patients of CC with positive CD133 expres-
sion had significantly better prognosis than those nega-
tive ones. Secondly, the patterns of CD133 expression
varied in different human CC cases and seemed to be
related to differentiation stages of the tumors. Like
glandular epithelia that usually show apical membrane
expression pattern of CD133 [20,33], normal bile ducts
showed the same expression pattern. Interestingly, simi-
lar expression pattern of CD133 was found in well-dif-
ferentiated CC. In contrast, poorly differentiated CC
cases usually showed solid growth pattern and most of
them were cytoplasmic positive or even negative for
CD133. Nevertheless, in the patients with pancreatic
ductal adenocarcinoma, there is no correlation between
the level of CD133 expression and patient survival [20].
However, Maeda S et al found that the 5-year survival
rate of CD133-positive patients was significantly lower
than that of CD133-negative patients [36].
Therefore, the role of CD133 expression in evaluating
prognosis of cancer patients needs to be explored in
further work. Until now, the physiological role of
CD133 is still elusive probably due to the occurrence of
many mRNA splice variants and the changing glycosyla-
tion status of the protein [37,38]. Moreover, the protein
has different subcelluar localizations (membrane, cyto-
plasm or both), which may confer different functions. It
also remains to investigate why CD133 is usually present
on apical membrane of normal bile ducts or other gland
lumen, why it is transferred from apical membrane to
cytoplasm in cancer cells and what its biological func-
tions in normal bile duct epithelium and cholangiocaci-
noma are. And the answers to these questions could
help us to understand the role of CD133 in the develop-
ment of CC and other tumors.
Conclusions
We found CD133 expressed mainly on the apical mem-
brane surface of bile ducts of all sizes and most of
malignant ducts. And the subcellular localization of the
CD133 protein was investigated and three staining pat-
terns, i.e. apical membrane, cytoplasm or both, were
presented in CC and the first pattern was frequently
found in well-differentiated CC. In addition, the positive
expression of CD133 was significantly correlated with
well or moderately differentiated CC and vice versa.
Moreover, the patients of CC with positive CD133
expression had a significantly better prognosis than
those negative ones. In brief, our study demonstrates
that CD133 expression correlates with the differentiation
of CC and indicates that CD133 is a potential indicator
for differentiation and prognosis of human CC, the
mechanisms of which, however, need to be investigated
in further study.
Additional material
Additional file 1: The differentiation grade and CD133 expression of
23 follow-up cases. The table contained the details of differentiation
grade and CD133 expression of all 23 follow-up cases. The differentiation
grade was classified as well-, moderately- and poorly-differentiated, and
the CD133 expression was presented with “+"as positive while “-” as
negative.
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